Who owns FPRX - FIVE PRIME THERAPEUTICS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

FIVE PRIME THERAPEUTICS INC - COM (FPRX) Institutional Ownership

Q: What is CUSIP 33830X104?

CUSIP 33830X104 is the security identifier used in SEC filing datasets for FPRX - FIVE PRIME THERAPEUTICS INC - COM.

CUSIP: 33830X104

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2021

Type / Class: Equity / COM
Symbol: FPRX

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 33830X104?
CUSIP 33830X104 identifies FPRX - FIVE PRIME THERAPEUTICS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 33830X104:

Q2 2021 (0 holders) Q1 2021 (143 holders) Q4 2020 (120 holders) Q3 2020 (88 holders) Q2 2020 (94 holders) Q1 2020 (79 holders) Q4 2019 (92 holders) Q3 2019 (100 holders) Q2 2019 (109 holders) Q1 2019 (111 holders)

Institutional Holders of FIVE PRIME THERAPEUTICS INC - COM (FPRX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2021 Q2	0	$0	-$1,555,487,625	$0	$0		0
2021 Q1	41,315,691	$1,556,341,973	+$401,187,467	$23,283,871	$10,010,767	$37.67	143
2020 Q4	38,992,067	$663,730,930	+$229,009,443	$3,386,406	$4,204,000	$17.01	120
2020 Q3	26,635,502	$125,164,517	-$4,465,416	$141,000	$203,000	$4.70	88
2020 Q2	27,310,534	$166,610,880	+$13,931,528	$0	$101,000	$6.10	94
2020 Q1	25,322,589	$57,483,608	-$5,167,576	$32,000	$51,000	$2.27	79
2019 Q4	26,680,062	$122,332,133	-$1,133,831	$0		$4.59	92
2019 Q3	27,036,775	$104,792,174	-$4,792,692	$474,000		$3.87	100
2019 Q2	27,704,329	$167,060,252	-$26,174,499	$189,000	$0	$6.03	109
2019 Q1	31,635,872	$424,146,366	+$13,926,605	$1,453,000	$735,000	$13.40	111
2018 Q4	30,912,149	$287,387,842	-$3,358,044	$803,000	$128,000	$9.30	112
2018 Q3	30,862,185	$429,661,693	-$7,372,496	$1,391,000	$2,087,000	$13.92	111
2018 Q2	31,018,077	$490,373,222	-$25,262,322	$884,000	$1,625,000	$15.81	118
2018 Q1	32,332,350	$555,217,759	+$96,760,885	$1,838,000	$359,000	$17.18	126
2017 Q4	25,971,527	$569,306,119	+$22,369,595	$3,610,000	$1,045,000	$21.92	132
2017 Q3	24,391,322	$997,239,355	+$3,352,630	$4,386,000	$6,252,000	$40.91	121
2017 Q2	24,497,990	$737,203,608	-$14,291,160	$2,125,000	$1,082,000	$30.11	120
2017 Q1	24,686,474	$892,383,878	+$38,075,158	$2,518,000	$1,687,000	$36.15	155
2016 Q4	25,061,140	$1,256,048,109	-$57,391,418	$0	$1,043,000	$50.11	172
2016 Q3	26,200,389	$1,375,221,575	+$120,468,170	$4,235,000	$378,000	$52.49	173
2016 Q2	24,525,470	$1,014,124,091	+$45,574,694	$5,184,000	$401,000	$41.35	169
2016 Q1	23,173,131	$941,398,135	+$39,798,681	$11,418,000	$2,564,000	$40.63	139
2015 Q4	22,183,174	$920,587,408	-$5,930,336	$11,532,000	$1,506,000	$41.50	128
2015 Q3	23,033,476	$354,482,689	+$34,055,152	$590,000		$15.39	109
2015 Q2	20,307,231	$504,412,047	+$42,143,941	$412,000		$24.84	106
2015 Q1	18,615,605	$425,488,294	+$106,161,341			$22.85	90
2014 Q4	13,682,541	$369,440,784	+$27,169,894			$27.00	71
2014 Q3	12,244,426	$143,625,701	+$7,961,526			$11.73	61
2014 Q2	11,393,348	$177,169,357	+$3,009,037			$15.55	61
2014 Q1	10,928,860	$214,864,101	+$82,437,037			$19.66	54